NCT01531894 2019-07-09Continuation Study of the Oral AKT Inhibitor GSK2110183NovartisPhase 2 Completed11 enrolled 8 charts
NCT01445587 2012-03-26A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple MyelomaGlaxoSmithKlinePhase 2 Withdrawn